

Features

- Standardized to ≥50% phytosterols (as β-sitosterol) by GC and ≥1% essential amino acids by HPLC.
- Controlled process and traceability.
- Made in Spain.
- Halal, Kosher and Doping-free certified.

Frequent urination during nights negatively affects health-related quality of life and sleep quality¹⁶

Differentiated value

- Unique proprietary combo of cereal pollen and pine tree extracts.
- Triple benefit in one solution: urinary symptoms improvement, prostate enlargement inhibition and prostate inflammation reduction¹⁻¹⁰.
- Unique ingredient assesing anti-proliferative effect of prostate precancerous cells at lower time and dose than other plant extracts, in vitro¹⁰.
- Lowest dose to get triple effect evoiding the use of multiple ingredients and high doses.
- Especially designed for men's healthy ageing demands.



Bioactive compounds

Plasys300[®] is standardized to ≥50% phytosterols (as β -sitosterol) by GC and to ≥1% essential amino acids by HPLC.

 β -sitosterol is a phytosterol that has clinical evidence as an inhibitor of testosterone production^{1,3,4}. Essential amino acids from rye pollen have a potent antioxidant effect and have been related to anti-inflammatory properties, as well as clinical evidence for palliating benign prostate hyperplasia symptoms (such as nocturia, urine frequency, bladder emptying and hyperplasia)^{2,5-10,12,13}.

Plasys300® reduces urinary disconfort

Bioactive compounds present in **Plasys300**® have shown clinical and animal evidence reducing the following urinary symptoms:

- Urinary urgency⁶.
- Urinary frequency and nocturia (frequent nighttime urination) 5,11.
- Urinary leakage^{6,7,9,14}.
- Sensation of residual urine^{3,14}.

Plasys300® helps maintain prostate healthy size

Inhibits cell proliferation.

Phytosterols from **Plasys300**® had an anti-proliferative effect on precancerous human prostatic cells at lower time and dose than other plant extracts, *in vitro*¹⁰.






Figure 1: Plasys300® phytosterols anti-proliferative assay on precancerous (hyperplastic) human prostatic cells.



Main mechanism of action

Plasys300® is acts mainly at three levels in a synergic way:

- 1. It **inhibits** one of the enzymes responsible for **testosterone production** (5- α -reductase), decreasing its concentration in the prostate and **balancing cellular growth factors levels** (such as SDGF* and EDGF**)³ typically altered inin an enlarged prostate or BPH.
- 2. It **blocks** the overstimulation of α -adrenergic receptors at the prostate, reducing the urinary tract vasoconstriction as well as the urinary discomfort symptoms^{11,12}.
- 3. It has an **anti-proliferative** effect at the prostatic cells that helps prevent prostate enlargement¹⁰.



References

(1) Berges A., et al. British J. of Urology. 2000; 85, 842-846. (2) Buck A.C., et al. British J. of Urology. 1990; 66, 398-404. (3) Berges RR., et al. Lancet. 1995; 345, 1529-1532. (4) Madersbacher S. et al. EAU-EBU. 2007; 5, 197-205. (5) Feinblatt H.M. and Gant J.C.. J. Maine Med. Assn. 1958; 9, 99-101. (6) Elist J. Urology. 2006; 67, 60-63. (7) Kimura M., et al. Japan Pharmacol. Ther. 1998; 26, 1801-1806. (8) Talpur N., et al. Mol Cell Biochem. 2003; 250, 21-26. (9) Yasumoto R., et al. Clin Therapy. 1995; 17, 82-86. **(10)** Inarejos-García A.M., et al. *Nutr. clín. diet.* hosp. 2017; 37(supl. 1): 45. (11) Bartsch G., et al. European Urology. 2000; 37, 367-380. (12) Caine M., et al. British Journal of Urology. 1976; 48, 255-263. (13) Damrau F., et al. J Am Geriatr Soc. 1962; 10, 426-430. (14) Klippel K.F., et al. British Journal of Urology. 1997; 80, 427-432. (15) Sampson N., et al. Molecular Endocrinology. 2001; 3,503-515. (16) Ancoli-Israel S,et al. Sleep Med Rev. 2011;15(2):91-97.

Botanical info

Botanical name: *Pinus spp* (tree bark) and *Secale cereale* (pollen).

Recommended daily dose

300 mg/day.

Other info

Shelf life: Two years*.

Non-GMO. Non-Irradiated.

Water-soluble.

Multiple applications.







"When stored at room temperature, sheltered from light and moisture.

Contact us

HEADQUARTERS AND MANUFACTURING PLANT

Ave. Del Dr. Severo Ochoa, 37, Local 4J. 28108 Alcobendas, Madrid (Spain). +34 91 112 38 48

QC AND R&D LABORATORIES

Calle Faraday, 7, 28049 Madrid (Spain). +34 91 112 38 48

info@pharmactive.eu
www.pharmactive.eu



The information contained herein is intended for marketing purposes only and for business to business professionals only. Not to be distributed as such to consumers, patients or sanitary professionals. At Pharmactive Biotech Products, S.L. we make every effort to keep all promotional material updated but do not guarantee the accuracy or completeness of the information provided herein. We disclaim any liability for use of this publication and reserve the right to change the content of this publication at any time without notice. The statements have not been approved by The European Commission or The Food and Drug Administration. All access and use of the information contained herein are at the user's own risk.

© 2020 Pharmactive Biotech Products, S.L. All rights reserved

PL0420EN